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Abstract
Degenerative changes in the plantar fascia may cause the so‐called “painful heel” with 
typical projections of tenderness. This condition is often associated with a plantar heel 
spur. Radiotherapy with low doses (LD‐EBRT) has been well known for its anti‐inflam‐
matory potential. In the recent years, several microbiological mechanisms were eluci‐
dated to explain immunomodulation by LD‐EBRT. Furthermore, a randomized study 
proved the clinical efficacy of this therapy in plantar fasciitis. Two other trials defined 
a fractionation schedule of 6 × 0.5 Gy twice weekly as the new standard therapy. Taken 
together, LD‐EBRT is an effective and safe therapeutic option for patients over 30 years of 
age and after exclusion of pregnancy. In case of an insufficient response, a second course 
can be offered to the patient. There are still open questions concerning target volume 
definition and fractionation of LD‐EBRT. Furthermore, studies randomizing LD‐EBRT 
with other conservative therapeutic approaches are missing.
Keywords: low dose radiotherapy, heel spur, plantar fasciitis, reizbestrahlung, target 
volume definition
1. Incidence and etiology of plantar fasciitis
About 7% of the population >65 years suffer from a painful heel, even though younger people 
are often affected, too [1]. The most common cause of this symptom is the so‐called “plantar 
fasciitis” [2]. This term is widely used, although “plantar fasciopathy” or “plantar fasciosis” 
would be a better description to point out the degenerative nature of the disease. However, as 
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more than 1100 citations in Pubmed quote “plantar fasciitis” (in comparison with only 50), we 
will use the traditional term in the following.
Plantar fasciitis has been associated with obesity, with acute or chronic work overload, or with 
work on hard surfaces [2, 3]. It seems that physiological degeneration of the fascia at the calca‐
neal insertion exacerbates due to repetitive microtraumas caused by vertical compression [4]. 
This causes inflammatory tissue reactions. As a result, the fascia is thickened with an associated 
fluid collection to 4.0 mm and more in ultrasonography [5]. Furthermore, this inflammation 
may trigger bone formation, the so‐called “plantar heel spur.” This process has been studied 
intensively by Kumai and Benjamin [6]. They proposed three stages of spur growth: “(a) an ini‐
tial formation of cartilage cell clusters and fissures at the plantar fascia enthesis; (b) thickening 
of the subchondral bone plate at the enthesis as small spurs form; and (c) development of verti‐
cally oriented trabeculae buttressing the proximal end of larger spurs” [6]. The first description 
of this spur formation and correlation with the clinical symptoms was carried out by Plettner 
in 1900 [7]. However, not every heel spur is associated with heel pain, as these spurs are found 
in 11–16% of the normal asymptomatic population [4]. On the other hand, some patients with 
painful plantar fasciitis do not have a radiographic confirmation of a spur formation.
A similar mechanism (although caused by longitudinal traction and not by vertical compression) 
of bone formation has been described at the insertion of the Achilles tendon [8].
According to the American clinical practice guidelines from 2010, diagnosis is established by 
the typical anamnesis and the characteristic localizations of tenderness. Still, weight‐bearing 
radiographs are also recommended [9].
2. Treatment with LD‐EBRT
2.1. Biological effects of LD‐EBRT on lymphocytes and inflammatory processes
Single doses of external beam radiotherapy (EBRT) in the range of 0.3–1 Gy are called “low dose 
EBRT” (LD‐EBRT). These single fractions are applied two or three times a week until a total 
dose of about 3–6 Gy is reached. Such radiotherapeutic concepts are used for diverse nonmalig‐
nant conditions, e.g., osteoarthrosis, tendinopathy, epicondylitis, or bursitis. A comprehensive 
review of the historical developments in LD‐EBRT for benign diseases is given by Trott [10].
In contrast, EBRT in oncology is characterized by much higher single and total doses. 
“Normofractionation” describes single doses of 1.8–2 Gy, applied about five times a week. 
To treat breast cancer, the total doses of about 62 Gy are necessary, in prostate cancer even 
more than 72 Gy. From a radiobiological point of view, these high cumulative doses are used 
to induce DNA double strand breaks. Due to errors in a repair mechanism (nonhomologous 
end joining), dicentric chromosomes can occur. These can result in unfinished mitoses, the 
so‐called “mitotic catastrophe,” the main mechanism to reduce clonogenic survival in tumor 
cells [11]. High doses of EBRT induce local inflammation and tissue reactions.
The much lower doses of LD‐EBRT act via different mechanisms. In the last two decades, 
several anti‐inflammatory effects have been discovered, contrary to the effects of the above‐
mentioned high EBRT doses.
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(a) In vitro LD‐EBRT has been shown to induce apoptosis in peripheral blood mononuclear 
cells (PBMC) [12]. Interestingly, there was not a linear correlation between dose and the 
amount of apoptotic cells. Instead, the maximal induction of apoptosis was observed after a 
single dose between 0.3 and 0.7 Gy, higher doses (up to 3 Gy) not being more effective [12].
(b) Furthermore, doses between 0.1 and 0.5 Gy reduced the adhesion of PBMC significantly to 
endothelial cells (ECs) in vitro, probably by suppressing the expression of L‐selectin on the 
surface of PBMC [13]. This is a very important finding, as the adhesion of leukocytes to the 
cells of the vessel wall is the first event of tissue invasion in inflammatory processes [13]. An‐
other reason for the reduced adhesion between PBMC and EC was identified by Rödel et al. 
[14]: In irradiated EC mRNA expression and protein secretion of transforming growth factor 
β1 (TGF‐β1) were highest after 0.5 Gy, higher doses resulted in a decline to basal levels [14]. 
Neutralization TGF‐β1 with specific antibodies restored the adhesion between PBMC and 
EC. These in vitro results were confirmed in vivo in a mouse model for 0.3 Gy [15]. TGF‐β 
expression is dependent on activation of the nuclear factor‐kappa B (NF‐κB) [16]. Also, NF‐
kB DNA‐binding activity showed a biphasic response to LD‐EBRT with a first maximum 
at 0.5 Gy, a relative minimum between 0.6 and 0.8 Gy, and a second increase at 1 and 3 Gy 
[16]. The above‐mentioned findings show a biphasic time course with reduced adhesion of 
PBMC 4 and 24 h after LD‐EBRT, with a relative maximum of adhesion after 12h [17].
(c) A third mechanism was the suppression of nitric oxide (NO) production in activated mac‐
rophages by LD‐EBRT between 0.3 and 1.25 Gy [18]. As the expression of inducible nitric ox‐
ide synthases (iNOS) proteins was not altered, the LD‐EBRT seemed to act at the translational 
or posttranslational level. Furthermore, a dose of 0.5 Gy significantly reduced oxidative burst 
and superoxide production of stimulated macrophages [19]. A diminished release of reactive 
oxygen species (ROS) can also contribute to the anti‐inflammatory effects of LD‐EBRT.
Taken together, all of these pathways and mechanisms showed a similar dose dependence with 
a maximum effect between 0.3 and 0.7 Gy regarding a discontinuous dose‐effect relation [20].
There are several in vivo studies in different animal models about the effects of LD‐EBRT, 
especially on osteoarthritis. A comprehensive overview is given in Ref. [20], however, as they 
are not directly related to calcaneodynia, we will not further comment on them.
2.2. Results of randomized trials on radiotherapy for painful heel spur
Since 1937 [21] for decades, large retrospective studies on the efficacy of LD‐EBRT in calcaneo‐
dynia have been published (overview in 22). In 1970, one negative randomized trial was reported 
and heavily criticized but had not been repeated [23]. Starting in the 1980s, patients were system‐
atically clinically examined and interrogated in a structured manner to try to control for diverse 
risk factors and to compare the efficacy of different fractionation schemes and total doses [24].
It took until the past decade to perform and report prospectively randomized trials to proof 
the efficacy of LD‐EBRT and to identify the optimal dose fractionation schedule. In the fol‐
lowing, we report the design and the results of these trials. Table 1 gives a short overview of 
the studied dose concepts and the results. Due to methodological reasons, we will describe 
the studies not following their publications dates, but according to a systematic order.
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2.2.1. Clinical proof of the efficacy of LD-EBRT
Since the publication of the first randomized trial on LD‐EBRT in 1970, the efficacy of LD‐
EBRT was questioned [23]. Goldie et al. randomized 399 patients, however, only nine patients 
suffered from calcaneodynia. This is why these results cannot be extrapolated to LD‐EBRT of 
a painful heel spur. Furthermore, endpoints were not clearly defined, and therapy was started 
in an acute stage of the disease [25].
The landmark study to prove the efficacy of LD‐EBRT was performed by the German coop‐
erative group on the radiotherapy for benign diseases (GCGBD) under the responsibility 
of Niewald et al. [26]. A very low dose EBRT (6 × 0.1 Gy applied twice a week up to a total 
dose of 0.6 Gy) was randomized to a standard dose LD‐EBRT (6 × 1 Gy twice a week up to 
a total dose of 6 Gy). In the case of an unfavorable response after 3 months, the patient was 
offered a second treatment series (“reirradiation”) applying a standard dose. The dosage of 
the experimental arm was chosen to examine if very low doses are effective at all. Second, 
it acted as a placebo irradiation, as a sham irradiation was regarded unethical. LD‐EBRT 
was applied using a linear accelerator (4‐ to 6‐MV photons) using lateral parallel opposing 
fields.
Inclusion criteria were tenderness of the calcaneus with a limitation of the painless walking 
distance and duration of the symptoms for more than 6 months. Furthermore, a radiological 
proof of a heel spur was required, and the patients had to be least 40 years of age. Patients 
with previous traumata to the foot, rheumatic or vascular diseases, lymphatic edema, preg‐
nancy, or breastfeeding were excluded. Concomitant therapy with oral analgesics was not 
limited. However, local injections with steroids during the study period were not permitted.
Author Year N Standard arm Experimental 
arm
Results Conclusions
Niewald et al. [26] 2012 66 6 × 1 Gy twice 
a week
6 × 0.1 Gy 3 months: VAS/CS/
SF12 sig. better with 
standard
1. Dose‐response 
relationship
1 year: less second 
treatment series with 
standard
2. Proof of 
therapeutic effect of 
LD‐EBRT
Heyd et al. [30] 2007 130 6 × 1 Gy twice 
a week
6 × 0.5 Gy 6 months: CS no sig. 
differences
6 × 0.5 Gy 
as standard 
fractionation
Ott et al. [32] 2014 457 6 × 1 Gy twice 
a week
6 × 0.5 Gy 6 weeks, 2.5 years: 
VAS/CS no sig. 
differences
6 × 0.5 Gy as 
standard confirmed
Niewald et al. [25] 2015 127 6 × 1 Gy twice 
a week
12 × 0.5 Gy 
thrice a week
3 months: VAS/CS/SF12 
no sig. differences
Efficacy not 
increased with 12 × 
0.5 Gy standard still 
6 × 0.5 Gy
Table 1. Summary of contemporary randomized trials on LD‐EBRT of painful heel spurs: tested schedules, results, and 
conclusions.
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Initially, 200 patients were planned [27] to detect a difference of 10% in the quality of life 
(QOL) sum score (SF‐12) [28] and calcaneodynia sum score (CS) [29] (Table 2) with a power of 
80% and an error probability of 5%. Furthermore, the visual analogue scale (VAS) to evaluate 
pain intensity was used. However, after randomization of 66 patients and interim analysis 
of 62 patients (4 had to be excluded due to a withdrawal of informed consent or violation 
of the inclusion criteria), the differences in efficacy between the two treatment arms were so 
pronounced, that the trial was closed early.
The mean age of patients was 54 years in the standard dose group and 58 years in the 6 × 0.1 
Gy group. Sixty‐one patients had a plantar, one patient a dorsal heel spur. In mean, patients 
in the standard dose group suffered for 15.3 months before the start of LD‐EBRT, in the 6 × 0.1 
Gy group for 18.8 months. Twenty‐one patients had symptoms on both sides. In 28 patients 
the pain irradiated into the calf, only in 18 patients it was localized to the sole of the foot. Two 
patients had received surgery for LD‐EBRT.
Criteria Extent of symptoms/alteration Points
1. Pain symptoms S = Pain at strain 6 / 4 / 2 / 0
(total: 30%) N = Pain during night time
D = Pain during day time (continuously)
R = Pain at rest (following any kind of strain)
I = Pain at initiation of movement/morning stiffness
none = 6 ; slight = 4 ; moderate = 2 ; severe = 0 points
⇨
6 / 4 / 2 / 0
6 / 4 / 2 / 0
6 / 4 / 2 / 0
6 / 4 / 2 / 0
per single criterion
2. Use of appliances
(total: 15%)
None
Orthopedic shoe, insoles, heel cushion
One cane or crutch
Two canes or crutches
⇨
15
10
5
0
3. Professional
activities
(total: 20%)
No limitation, maximum professional strain possible
Slight limitation, normal professional work possible
Moderate limitation, reduced professional activity
Severe limitation, daily professional work impossible
⇨
20
10
5
0
4. Daily/leisure activities
(total: 15%)
No limitation of daily and leisure activities and sports
Slightly limitation/reduced leisure activities and sports
Moderate limitation/no leisure activities and sports
Complete limitation of any daily and leisure activities
⇨
15
10
5
0
5. Gait/limp
(total: 20%)
No limp, normal walking is possible without a limitation
Slightly altered, limp after walking > 1 km (2 blocks)
Moderately altered, limp after walking < 1 km (2 blocks)
Severely altered, normal walking is impossible
⇨
20
10
5
0
Total score Sum of the single scores 1 + 2 + 3 + 4 + 5 ⇨
Table 2. Calcaneodynia score of the GCG‐BD [29], based on [31].
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Three months after therapy VAS values, CS‐ and QOL‐scores were significantly better after 
the standard dose in comparison with the very low dose treatment arm. The higher pain 
relief resulted in a better QOL. Twelve months after therapy about 64% of the patients after 
6 × 0.1 Gy had to receive a second treatment series due to insufficient treatment results, in 
comparison with only 17% of the patients in the standard dose treatment group. As the sec‐
ond series was applied with a standard dose (6 × 1 Gy), patients in the 6 × 0.1 Gy group who 
were reirradiated showed equally favorable results compared with those in the standard‐dose 
group who did not receive a second course [26]. This is why the second treatment series in 
this clinical setting acted as a “salvage therapy.” Another interesting finding was that patients 
with a good response already at 3 months remained stable or even improved at 12 months. 
Furthermore, this underlines the long‐lasting efficacy of LD‐EBRT.
Acute side effects or long‐term toxicity did not occur.
In conclusion, this randomized trial established a dose‐response‐relationship of the analgesic 
effect of LD‐EBRT, thus providing a clinical and methodological proof of the efficacy of 6 × 1 Gy 
LD‐EBRT on the clinical course of painful heel spurs. The early termination of the study was jus‐
tified due the interim analysis showing significant differences in the clinical outcome between 
both treatment arms. Still, the trial was not blinded, so both the patients and the staff were 
aware of the received dose. With modern linear accelerators, a complete blinding of the staff is 
nearly impossible. The only option would be a shame irradiation with closed collimator jaws, 
reducing the dose to the unavoidable “leakage” radiation. A much easier and straight forward 
way was used in the above‐mentioned study by application of a minimal physical dose with 0.1 
Gy. Another critical point might be that only half of the patients were examined 12 months after 
therapy (n = 36). This reduces the reliability of the study results at this time point. However, this 
does not affect the results concerning treatment efficacy 3 months after LD‐EBRT.
Another potential confounder not only in this study but also in all other published prospec‐
tive and retrospective case series might be that a lot of the patients had received diverse and 
other conservative therapies before being referred to LD‐EBRT. An interaction between one 
of these other treatments and LD‐EBRT cannot be ruled out due to methodological reasons. 
This reflects clinical reality. Still, an interaction between one of these therapies and LD‐EBRT 
is rather unlikely and counter‐intuitive, as patients were referred to LD‐EBRT after the clinical 
failure of all the other conservative treatments.
2.2.2. Looking for the minimum effective dose: optimization of fractionation and total dose of LD-EBRT
2.2.2.1. Single dose 0.5 vs. 1 Gy
Two randomized studies investigated the efficacy of 0.5 Gy single dose in comparison to 1 Gy.
The first trial was conducted by Heyd et al. [30]. They randomized 130 patients between 6 × 
0.5 Gy twice weekly (low dose) and 6 × 1 Gy (standard dose). A linear accelerator was used, 
applying a single field technique.
Inclusion criteria were clinical signs of a painful heel spur, radiological evidence of spur 
formation, patient age ≥30 years and a relapse after previous conservative treatments, in 
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patients >45 years LD‐EBRT could be used as the primary treatment. Endpoints of the study 
were changes in the “original” calcaneodynia score [31], that was documented before LD‐
EBRT, at the end of the course, and 6 weeks and 6 months afterward.
One hundred and thirty patients were randomized. Mean age was 58.4 years. A 102 patients 
suffered from a plantar, one patient from a dorsal, and 27 patients from combined spurs. 
In mean, patients had been suffering from symptoms for 9.8 months. The symptoms had 
been present in 58 patients for less than 6 months, in 72 patients for a longer time. In 7 heels 
LD‐EBRT was the first therapeutic approach.
At the end of LD‐EBRT, 66% in the low dose group vs. 59% in the standard dose experienced 
an improvement in symptoms, 6 weeks later 80 vs. 85%. At this time point, 1.5% in each 
group reported an increase in symptoms, 19 vs. 14% no change. No statistically significant 
differences were noted. In case of insufficient treatment results patients were offered a second 
EBRT series. Thus 26 vs. 37% were treated a second time. Six weeks after that, 71 vs. 79% of 
these patients reported a further improvement. Six months after LD‐EBRT 88% of the patients 
in both groups had an amelioration of their symptoms, the remaining patients reported no 
change. During the EBRT series a slight increase in pain was reported by 26 vs. 29% of the 
patients. No other acute or late toxicity occurred.
In conclusion, 6 × 0.5 Gy twice weekly was as effective as 6 × 1 Gy.
These results were confirmed by a second randomized trial [32, 33]. Ott et al. randomized 457 
patients between 6 × 0.5 Gy (low dose) and 6 × 1 Gy (standard dose). In contrast to the above‐
cited “Heyd‐study” [30] an X‐ray unit (orthovoltage) and not linear accelerators was used. 
Patients received a single field (6 × 8 cm on the plantar calcaneus) with 150 kV, 15 mA, 1 mm 
Cu‐filter, with source‐to‐skin distance (SSD) of 40 cm. Six weeks after the LD‐EBRT a second 
series was offered to patients with an insufficient response. The endpoint was pain reduction. 
CS score and VAS values were measured before and at the end of LD‐EBRT (early response), 
6 weeks (delayed), and 2.5 years (long‐term) afterward.
With a median follow‐up of 32 months the mean VAS values before treatment, for early, 
delayed, and long‐term response for the 0.5 and 1.0 Gy groups were 65.5 ± 22.1 and 64.0 ± 20.5 
(p = 0.19), 34.8 ± 24.7 and 39.0 ± 26.3 (p =0.12), 25.1 ± 26.8 and 28.9 ± 26.8 (p =0.16), and 16.3 ± 
24.3 and 14.1 ± 19.7 ( p =0.68) [31]. Similar results were obtained for the CS score without any 
significant differences between both dose groups.
Taken together, the above‐mentioned studies proofed an equivalent clinical efficacy of 6 × 0.5 
Gy in comparison to 6 × 1 Gy, thus defining a new clinical treatment standard with six times 
0.5 Gy twice weekly as the minimum effective dose.
Before proofing 0.5 Gy as the new standard single dose, another randomized study tried to 
increase efficacy in reaching the “old” cumulative dose of 6 Gy with a single dose of 0.5 Gy. 
Niewald et al. randomized between 6 × 1 Gy twice a week (old “standard dose”) and 12 × 0.5 
Gy three times a week (“experimental dose”) [25]. The aim was not just to get comparable 
results, but to further improve the analgesic effects. Linear accelerators (6 MV photons) apply‐
ing a lateral opposing field technique were used.
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Inclusion and exclusion criteria were quite similar to the ones used in the landmark 
study [26]: Clinical evidence of a painful heel spur, and duration of the symptoms for more 
than 6 months; radiological proof of a spur formation; age at least 40 years; Karnofsky‐Index 
at least 70%. Patients with previous radiotherapy or previous trauma to the foot, rheumatic 
or vascular diseases, lymphatic edema, pregnancy, breastfeeding, or severe psychiatric dis‐
orders were excluded. Concomitant therapy with analgesics was allowed. However, patients 
receiving surgery or shock wave therapy after randomization were excluded.
Endpoints were the SF‐12 sum score, the CS sum score (Table 2), and VAS. Follow‐up was 
scheduled every 6 weeks for 1 year.
Two‐hundred and forty patients were calculated to detect a difference of 15% in the VAS and 
CS score, with a power of 80%, and an error probability of 5%. After randomization of 127 
patients and an interim analysis of 107 patients, the study was closed early, as the intended 
increase in analgesic efficacy by the experimental treatment was very unlikely to be achieved.
The mean age of the patients in the standard group was 56.1 Gy in comparison with 58.1 Gy 
in the experimental group. The mean duration of symptoms before initiation of LD‐EBRT was 
17 vs. 16 months. In 98% of the standard group and 93% of the experimental group a plantar 
spur was treated, in 2 and 7% a combined (plantar and dorsal) spur.
Results after 3 months have been issued so far [25], longer follow‐up has yet to be published. 
After 3 months, there were no significant differences neither in the VAS (standard 42.3 vs. experi‐
mental 44.4) nor the CS sum score (28 vs. 28.4) nor in the QOL (SF‐12) scores. Although longer fol‐
low‐up has to be awaited, a further increase in the analgesic effect by applying 12 × 0.5 Gy three 
times a week is unlikely. This is why this fractionation schedule is currently not recommended, 
as it does not follow the “as low as reasonable achievable” principle of radiation protection.
2.2.2.2. Single dose 0.3 vs. 1 Gy
Further reduced single doses in LD‐EBRT (with the exception of 0.1 Gy [26]) have never been 
tested in a prospectively randomized clinical trial. In radiotherapy of degenerative joint dis‐
orders, single doses of about 0.3–0.4 Gy were established by von Pannewitz in the late 1920s 
and published in 1933 and 1970 [34, 35]. However, two studies on calcaneodynia have raised 
serious concerns on single doses as low as 0.3 Gy.
Seegenschmiedt et al. analyzed treatment efficacy in 141 patients (170 irradiated heels), who 
were treated from 1984–1994 with X‐ray units (250 kV/200 kV, 20 mA, 40 cm SSD), applying 
a single field of 6 × 8 cm [24]. Seventy‐two heels received 12 Gy with 6 × 1 Gy (three times a 
week) –6 weeks break – 6 × 1 Gy (group A), 50 heels were treated with 10 × 0.3 Gy every day 
(group B1), and 38 heels 10 × 0.5 Gy every day (group B2). The endpoint was the value of a 
semiquantitative pain score 3 months and in mean 4 years after LD‐EBRT.
The median age of patients was 55 years in group A and 59 years in group B1/B2. The mean 
duration of symptoms before LD‐EBRT was 8 months, in one‐third, the symptoms persisted 
for more than 6 months.
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Complete pain remission was achieved in 68–71% of the patients without significant differences 
between the treatment groups. However, there were differences in the clinical course of patients 
with partial remission of the symptoms: The best results in these patients were achieved during 
longer follow‐up in group B1 (10 × 0.5 Gy), followed by group A (6 × 1–6 × 1 Gy), followed by 
group B2 (10 × 0.3 Gy). The latter group showed a significantly worse amelioration of symp‐
toms than the other groups.
A reduced efficacy was also reported in another retrospective case series, comprising 673 
heels treated with a single dose of 0.3 Gy three times weekly up to 1.5 Gy (X‐ray) [36]. 
In case of insufficient treatment results the patients were offered a second course. After 
the first treatment, only 13% reported CR, nearly all patients had undergone a second 
LD‐EBRT.
Taken together, to the best of our current knowledge a single dose of 0.5 Gy is standard of care 
and should only be modified in controlled clinical trials.
2.3. Risk factors potentially associated with treatment failure
In Table 3 selected contemporary randomized trials and patient series are shown broken 
down into several factors that might be correlated with treatment efficacy. For a better over‐
view, we did not differentiate between univariate and multivariate analyses. We did not try 
to collect all ever published data.
2.3.1. History of symptoms
Duration of symptoms before start of LD‐EBRT has been shown to be correlated with treat‐
ment efficacy in numerous studies.
Muecke et al. analyzed in a retrospective multicenter study 502 patients [22]. Duration of 
symptoms ≤6 months was associated with 76% treatment success vs. 44% after a history >6 
months. Also Seegenschmiedt et al. found in their large collectives a correlation between the 
duration of heel pain and treatment outcome [24]. A significant influence of duration of symp‐
toms before LD‐EBRT was also reported in 73 heels by Schneider et al. [37]. With a history 
of 3–6 months, the VAS value was reduced by 85%, 28 months after LD‐EBRT in comparison 
with a reduction of 58% with a history > 6 months. Similar results were obtained by Hermann 
et al. in 285 heels comparing <12 month history of pain vs. >12 months [38].
In contrary, another study could not confirm these results [30].
2.3.2. Gender
To the best of our knowledge, in no study, an influence of gender on treatment outcome 
has been confirmed [22, 24, 30, 38, 39]. In contrast to radiotherapy for oncological indica‐
tions with high doses, efficacy and tolerability of LD‐EBRT seems to be the same concerning 
gender.
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Study (citation) [30] [26] [24] [37] [39] [22] [38] [40] [83]
Type Rand Rand Prospect Prospect Retrospect Retrospect Retrospect Retrospect Retrospect
Number of heels 130 66 170 73 623 502 285 161 7947
Energy MV MV KV MV KV MV, KV MV KV MV, KV
Target volume calcaneus calcaneus calcaneus entire dorsal and 
middle foot
insertion of 
plantar fascia
calcaneus calcaneus vs. 
insertion of 
calcaneus
calcaneus entire dorsal foot 
vs. calcaneus 
vs. insertion of 
plantar fascia
Dose 6 × 1 vs. 6  
× 0.5 Gy
6 × 1 Gy vs.  
6 × 0.1 Gy
12, 3, 5 Gy 5 Gy (increasing 
single dose)
1.5 (1–3) up to 
9–12 Gy (1–45)
5–10 × 0.5–1 Gy 6 × 1 Gy6  
× 0.5 Gy
6 × 1 Gy 0.3–1.5 Gy; 2–3x 
weekly 2.5–18.76 
Gy
Potential factors
History of 
symptoms
0 n.i. + + 0 + + + +
Gender 0 n.i. 0 n.i. 0 0 0 n.i. n.i.
Patient's age 0 n.i. 0 + 0 + + + n.i.
Initial worsening 
of pain during 
LD‐EBRT
n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i.
MV vs. KV n.i. n.i. n.i. n.i. n.i. + n.i. n.i. 0
Number of 
therapy series
n.i. n.i. n.i. + n.i. + n.i. n.i. +
Heel stress during 
LD‐EBRT
n.i. 0 n.i. + n.i. n.i. n.i. n.i. n.i.
Note: 0: no correlation with treatment outcome; +: correlation with treatment outcome; n.i.: not investigated; prospect: prospective case series; rand: randomized clinical 
trial; retrospect: retrospective case series; KV: kilovoltage; MV: megavoltage.
Table 3. Factors associated with treatment efficacy in contemporary studies.
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2.3.3. Patients’ age
Several studies described a correlation between older age and better treatment results, at least 
6 weeks after LD‐EBRT [37]. Age somewhat over 50 years seems to be important: >50 years 
[40], > 53 [38], or > 58 [22]. For a possible explanation see Section 2.3.7.
However, other studies found no influence of this patient characteristic on treatment outcome 
[24, 30, 39].
2.3.4. Initial increase in pain during LD-EBRT
A very precise registration of changes in pain intensity (VAS) was done by Schneider at al. [37]. 
Sixty‐two patients (73 treated heels) were prospectively scored every week during LD‐EBRT, at 
the end of therapy, 6 weeks, 28 months, and 40 months later. Additionally, subjective mechani‐
cal heel stress during LD‐EBRT was estimated. A linear accelerator (10 MV) was used, applying 
one single field with a size of 12 × 17 cm. Patients were treated twice a week to a total dose of 
5 Gy, with increasing single fraction doses (0.25 – 0.25 – 0.5 – 1 – 1 – 1 – 1 Gy). Mean patient 
age was 54 years, and all had a radiologically proven plantar spurn, mean symptom duration 
before LD‐EBRT was 6.5 months. Nearly all patients had received other conservative therapies 
before LD‐EBRT with insufficient results.
Interestingly, VAS scores decreased continuously during LD‐EBRT: before treatment the mean 
value was 6.3 ± 1.5, after the first week of LD‐EBRT 6.2 ± 1.8, after the second week 5.5 ± 2 (p < 
0.05), after the third 4.7 ± 2.4, and 3.8 ± 2.1 at the end of therapy (p < 0.001). Six weeks later the 
value further decreased to 3 ± 2.5 (p < 0.004), 28 months after LD‐EBRT to 1.6 ± 2.2 (p < 0.01). 
One year later no further decrease was noticed (1.8 ± 2.3). Only two patients reported intensi‐
fication of pain during the LD‐EBRT series. However, these data are not to be extrapolated, as 
increasing single doses (see above) were used to avoid this phenomenon.
In standard schedules with fixed single doses a slight increase in pain during the treatment series 
was reported by 26% (during 6 × 0.5 Gy) vs. 29% (6 × 1 Gy) of the patients [30]. Unfortunately, 
a possible correlation of this phenomenon with definite treatment results was not investigated.
Without further quantification, another study (6 × 1 vs. 6 × 0.1 Gy) stated, that this initial 
increase in symptoms “had no influence on the final pain relief 3 and 12 months after treat‐
ment” [26]. Older studies postulated a temporary reduction of the pH value in the irradiated 
tissues at the beginning of the treatment series, without consequences for the long‐term effi‐
cacy of LD‐EBRT [41].
This is contrasted by observations of LD‐EBRT in peritendinitis humeroscapularis [42]. In 
73 patients (86 shoulders) initial increase of pain during the treatment course was signifi‐
cantly associated with a good response.
2.3.5. Use of megavoltage techniques/linear accelerators
Muecke et al. analyzed in a retrospective multicenter study the influence of different treat‐
ment techniques in 502 patients [22]. Treatment failure was defined as pain persistence after 
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LD‐EBRT and recurrence of pain during follow‐up. Treatment with MV (6–10 MV) was a 
significant prognostic factor for pain relief in multivariate analysis, as MV was associated 
with an eight‐year event‐free probability of 68 vs. 61% after X‐ray beams (175 kV). There 
are two possible explanations for this finding: besides the possibility of a random result, the 
authors postulate a more homogenous dose distribution with MV treatment in comparison 
with KV [22].
2.3.6. Number of therapy courses required
Schneider et al. reported an efficacy of just one‐third after a second LD‐EBRT course (so‐
called “re‐irradiation”) in comparison with the effects of the first course [37]. Out of 73 
heels treated with 5 Gy LD‐EBRT 18 heels received reirradiation due to insufficient treat‐
ment response. However, pain reduction measured by means of changes in VAS shortly 
after the second course and during long‐term follow‐up was significantly diminished in 
comparison with the efficacy of the first course (about 30% reduction in pain at the last 
evaluation vs. 86%).
Similar results were obtained in the large retrospective series (502 patients) by Muecke et al. [22]. 
Treatment failure was significantly associated with the number of treatment series: eight‐year 
event‐free probability was about 70% after the first course in comparison with just about 30% 
after reirradiation.
A systematic study on the efficacy of a reirradiation has been published by Hautmann et al. 
[43]. Eighty‐three patients (101 heels) with insufficient response to the first course or recurrent 
pain afterward due to plantar fasciitis (83 heels), or achillodynia (28 heels) received a second 
LD‐EBRT course in median 10 weeks (range 4 weeks to 63 months) after the first LD‐EBRT. 
About 75% of the patients were treated with 6 × 1 Gy, the others 6 × 0.5 Gy. The pain was 
assessed using the numeric rating scale (NRS) before and at the end of LD‐EBRT, 6, and 12 
weeks, and 6, 12, and 24 months thereafter.
Before reirradiation NRS values were 6 (interquartile range 5–8), at the end of LD‐EBRT 5 
(2–6), 6 weeks later 2 (1–4), at 12 weeks 1 (0–3), at 6 months 0 (0–2), at 12 and 24 months 0 (0–1). 
Interestingly, not only the patients with recurrent pain after the first course but also patients 
with insufficient responses to the first course experienced a profound and long‐lasting ame‐
lioration of their symptoms after the second course.
This is why a second treatment course should be recommended in case of insufficient efficacy 
of the first course.
2.3.7. Heel stress during LD-EBRT
A significant correlation between avoidance of heel stress during LD‐EBRT and efficacy of 
LD‐EBRT 6 weeks after therapy was reported by Schneider et al. in 73 heels [37]. With a 
Pearson's correlation coefficient of ‐0.467 (p < 0.01) there was an impressing influence of this 
variable on pain reduction measured by VAS values. However, this correlation was not seen 
28 and 40 months after LD‐EBRT.
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An intuitive explanation is given by the authors [37]: As patient age was associated with posi‐
tive treatment results, too, they proposed that older patients are often retired, thus being able 
to take more care of their heels.
2.3.8. Spur size
Interestingly, all randomized trials required the radiological proof of a heel spur before including 
patients into the studies. Furthermore, most of the prospective and retrospective series warranted 
such an objective sign. However, as a substantial part of the patients suffers from plantar heel 
pain without having developed a heel spur, LD‐EBRT should be effective in these patients, too.
Hermann et al. analyzed treatment efficacy in 250 patients (285 heels), who received 
LD‐EBRT predominantly with 6 × 1 Gy [38]. In this series, 33% of the treated heels were 
without radiological evidence of a spur. In 185 patients a spur was confirmed with a mean 
length of 6.5 mm (range 0.6–25 mm). Patients without evidence of a plantar heel spur had 
a significantly higher chance of CR after LD‐EBRT (43 vs. 35%). Furthermore, the length of 
the spurs correlated directly with treatment outcome. Spurs >6.5 mm had just a 30% chance 
of experiencing CR in comparison with shorter ones. No statistical differences were found 
between treatment results of heels without spurs and those with spurs ≤6.5 mm.
Miszczyk et al. reported on 327 patients (623 LD‐EBRT series) mostly treated with X‐ray (180 kV, 
usually 1mm Cu filters) with single doses of 1.5 Gy (range 1–3 Gy) up to a total dose between 9 
and 12 Gy (range 1–45 Gy) [39]. Mean spur size was 9 mm (range 1–30 mm). With a mean follow‐
up of 74 months, no correlation between spur size and duration of pain relief was found. Analysis 
concerning spur length and treatment outcome in itself were unfortunately not reported.
2.3.9. The combination of different factors
Multivariate logistic regression enables the identification of factors independently predicting 
treatment outcome. By combining these factors, models can be calculated, that predict treat‐
ment outcome with a high probability. An example from the study of Hermann et al. is given 
in Table 4: in 285 heels treated with 6 × 1 Gy/6 × 0.5 Gy the influences of the patient character‐
istics age, spur length, and duration of symptoms before LD‐EBRT alone and in combination 
were calculated [38]. The best results were obtained for patients > 53 years, spur length <6 
mm, and a duration of symptoms <12 months with a probability for CR of 55% (CI 36–73%) 
and PR of 38% (CI 22–58%). Without these characteristics, the chance for CR was just 18% (CI 
9–33%), for PR 31% (17–48%).
2.4. Technique
In modern radiotherapeutic departments, X‐ray sources are less and less available. This is why 
nowadays most patients are treated with linear accelerators, which were initially developed for 
the treatment of oncological diseases. However, these machines can be used in the treatment 
of benign diseases without any modifications or problems. Due to the high efforts in physical, 
technical, and organizational quality assurances for the operation of an accelerator or an X‐ray 
source, the concentration on accelerators and their use for all indications is recommended.
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For irradiation of the heel, the patient has to be placed on the treatment couch with the feet 
toward the gantry of the accelerator (so‐called “feet first”). Two different patient positions 
are widely used. He can be placed in supine position, with the irradiated leg is stretched 
out, while the other leg is angled. Another option is to place the patient in a lateral decubitus 
position on the side of the involved heel. Again, the symptomatic leg is stretched, while the 
contralateral leg is bent, with a cushion placed beneath the knee. Using X‐rays, the ipsilateral 
knee is bent by 90% and the foot is positioned on the treatment table. One anterior‐posterior 
(AP) beam is usually applied in this technique.
For the treatment itself, there are also two different options. Irradiation may be given as a single 
stationary field (SSD 100cm by convention). Alternatively, parallel opposing fields from 0° and 
180° gantry position (in decubitus position) or lateral opposing fields (90° and 270° in supine 
position) are also applicable but take a little bit longer in daily clinical practice. The hypothetical 
advantage of using two opposing fields is a uniform dose distribution in the entire beam path in 
the calcaneus (Figure 1). However, there has never been a clinical proof, whether this theoretical 
assumption translates into any clinical advantage for the patient. When applying opposing fields, 
the dose is specified according to the ICRU 50 report, normally in the center of the calcaneus.
A third option is the so‐called “plantar field” with the patient lying in prone position. A single 
field is positioned directly over the plantar insertion/calcaneus, potentially with rotations of 
the patient table and the gantry to compensate for inclinations of the patients surface in the 
irradiated field. However, this technique is regarded problematic when using linear accelera‐
tors due to the dose build‐up effect in the critical tissue depth. This problem is illustrated in 
Figure 2: photons with 6 MV reach just the half of the prescribed dose at the skin level, 100% 
is reached at 1.5 cm tissue depth. This would result in an insufficient dose in the critical struc‐
tures (plantar fascia and heel spur). To overcome this problem, a silicone flap of about 1 cm 
diameter must be positioned on the skin before radiation.
Patient's  
age >53
No spur or  
spur ≤6.5 mm
Duration of 
symptoms  
<12 months
Probability of
No change Partial remission Complete 
remission
1 1 1
0.07 (0.03–0.14)
0.38 (0.22–0.58) 0.55 (0.36–0.73)
1 1 0 0.13 (0.07–0.28) 0.37 (0.21–0.57) 0.50 (0.30–0.70)
1 0 1 0.15 (0.06–0.24) 0.53 (0.33–0.72) 0.32 (0.17–0.53)
1 0 0 0.25 (0.13–0.45) 0.48 (0.27–0.69) 0.27 (0.13–0.48)
0 1 1 0.17 (0.10–0.31) 0.33 (0.19–0.50) 0.50 (0.33–0.66)
0 1 0 0.34 (0.20–0.53) 0.40 (0.24–0.59) 0.26 (0.13–0.45)
0 0 1 0.30 (0.20–0.46) 0.29 (0.18–0.43) 0.41 (0.27–0.56)
0 0 0 0.51 (0.35–0.69) 0.31 (0.17–0.48) 0.18 (0.09–0.33)
Table 4. Probabilities (95%‐CI) for NC, PR and CR calculated by polytomous logistic regression in dependence of the risk 
factors age, spur length, and duration of symptoms before LD‐EBRT according to Hermann et al. in a collective of 285 
heels treated with 6 × 1/6 × 0.5 Gy (taken from [38]).
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Figure 2. Depth curves of different megavoltage energies. Blue 6 MV photons, red 15 MV photons. At the surface of the 
body/skin (depth 0 mm), only half (or even less with 15 MV) of the prescribed dose is applied. By physical interactions 
between photons and the tissue/water, there is a steep increase in dose. A 100% is reached at 1.5 cm depth with 6 MV and 
at about 3 cm depth with 15 MV. KV‐radiation reaches the maximum dose directly under the surface/skin (not shown). 
More information is given in Section 2.4.
Figure 1. Dose distribution of two different treatment techniques generated in a treatment planning system (XIO®). In 
A and B just one single 6 MV photon field (8 × 8 cm) is applied, while C and D shows the dose distribution with two 
opposing fields from 0 and 180°. In the upper row, the so‐called “beams eye views” are given, while in the lower row the 
respective dose distributions on an axial CT scan directly at the calcaneal insertion are shown. Note the more uniform 
dose distribution with opposing fields. The 95% isodose is given as a green line (2.85 Gy). This dose encompasses larger 
parts of the calcaneal bone in D (opposing fields) than in B (single field). More information is given in Section 2.4.
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3. Toxicity and potential risks of LD‐EBRT
Patients are often sent to the radiotherapist after a long unsuccessful history of diverse conserva‐
tive treatments. The reason for this is a widespread fear among general practitioners that LD‐
EBRT might be associated with severe side effects and risks. These fears are not substantiated, as 
reactions of the nerves or vessels require much higher doses than used for LD‐EBRT. For exam‐
ple, a dose of 45 Gy in normofractionated oncological therapy is considered to be safe for the spi‐
nal cord and therefore daily clinical practice [44]. Peripheral nerves are even more radioresistant. 
Acute or chronic side‐effects have never been reported in all contemporary studies on LD‐EBRT.
3.1. Acute reactions of the skin
Acute side effects are negligible, as very low doses of ionizing radiation (in comparison with 
oncological treatments) are applied to a distal extremity. The total dose of LD‐EBRT with 3 
or 6 Gy is far too low to cause any acute or late reactions on the skin overlaying the calca‐
neus. During normofractionated EBRT (single doses of 1.8–2 Gy, treatment on 5 days a week) 
erythema and mild edema develop at about 30 Gy [45]. Hyperpigmentation occurs at about 
45 Gy, moist epitheliolyses at about 50 Gy. A 50–60 Gy might cause telangiectasias years after 
the therapy. This is why there is no report on acute treatment side effects in LD‐EBRT until 
now to the best of our knowledge.
3.2. Initial increase in pain during LD‐EBRT
About one‐third of the patients might experience a slight increase in pain during LD‐EBRT. In 
the randomized trial by Heydt et al. this phenomenon was seen in 26% (during 6 × 0.5 Gy) vs. 
29% (6 × 1 Gy) [30]. It does not seem to be correlated with treatment outcome; further detailed 
information is given in Section 2.3.4.
3.3. Impairment of gonad function
The dose scattered to the male gonads is somewhat higher than to the ovaries. Jansen et al. 
calculated for 6 × 0.5 Gy about 1.5 mSv received by the testes and 0.75 mSv to the ovaries [46]. 
Comparable results have repeatedly been measured in the past [47, 48].
Taken together, the dose received by the gonads is insignificant. As the distal extremity is irra‐
diated, scattered dose to the gonads is comparable to normal diagnostic radiological imaging 
[49]. The hereditary effects of these doses are very small and very likely negligible [46].
Although spermatogonial cells are very radiosensitive, a single dose of at least 100 mSv is 
needed to induce a temporary failure of spermatogenesis [50]. A single dose of 1000 mSv 
(equivalent to 1 Gy photon irradiation) results in an azoospermia for 9–18 months [51]. 
Interestingly, fractionated doses harm these cells even more. A temporary oligospermia is 
reported after receiving several fractions up to a cumulative dose of 160 mSv [52]. An azo‐
ospermia lasting for 14–22 months has been reported for fractionated doses of 620–860 mSv 
[53]. The actually during LD‐EBRT received testicular dose is about 100 times smaller than the 
lowest dose causing temporary changes in testicular tissues.
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The dose to the testicles can be further reduced by utilizing a special testicular shielding. 
However, clinically meaningful dose reductions have been only measured in MV treatment 
of subdiaphragmatic/pelvine lymphatic regions or tumors [54, 55].
The mean lethal dose for human oocytes has been estimated at 2 Gy (2000 mSv) [56]. Permanent 
ovarian failure after radiotherapy is age dependent: in perimenopausal women, a dose of 6 
Gy is sufficient [57], while in younger women up to 20 Gy are tolerated. The dose scattered to 
the ovaries during LD‐EBRT for calcaneodynia cannot cause such sequelae (0.75 mSv).
Naturally, pregnancy has to be excluded in all premenopausal women before beginning with 
LD‐EBRT, to avoid any risk to the fetus.
3.4. Induction of malignancies
So far, no studies with long‐term observation periods have been published, describing a case 
of malignancy induced by LD‐EBRT for calcaneodynia. However, induction of malignancies 
is a stochastic effect of ionizing radiation. This means that there is no threshold dose—in 
contrast for example to the above‐mentioned reactions of the skin. A photon can accidentally 
trigger a mutation, which in turn leads to tumor formation many years later. The higher the 
radiation dose, the higher the probability of such an event occurring.
The best available data on tumor induction of full dose EBRT in oncology has been col‐
lected in patients treated with breast cancer. Almost 11,000 patients have been followed 
for over 20 years. The risk of a radiation‐induced tumor was approx. 1% per decade after 
radiotherapy [58].
To estimate the risk associated with much lower doses of LD‐EBRT, mathematical models 
on the basis of epidemiological long‐term observations of atomic bomb victims have been 
developed by the ICRP [59].
Jansen et al. applied the ICRP model on LD‐EBRT of a painful heel spur [46]. Assumed was 
a single field entering at the foot sole with a size of 8 × 10 cm, 200 kV photons, SSD 40 cm. 
For an LD‐EBRT series with 6 × 1 Gy the average attributable lifetime risk for induction of a 
fatal tumor was calculated to be about 0.5 in a thousand patients. An important risk factor for 
radiogenic‐induced cancer is the patient's age by the time the radiation exposure occurs. The 
risk is already reduced in the 3rd decade of the patient's life, it starts to decrease steadily from 
the age of 40 [60]. Applying these calculations, the estimated lifetime risk per one thousand 
patients for a fatal tumor accounts for the age of 25 0.6 (male)/0.8 (female), for the age of 50 
0.2/0.3, for the age of 75 0.07/0.1 [46].
However, it must be critically noted that this mathematical model was developed for radia‐
tion protection and relates to the exposure of complete organ systems with approx. 1 Gy. 
Therefore, other groups argue that a significantly lower risk of radiogenic cancer induction— 
approx. ten times less—should be adopted [49, 61]. Furthermore, taken the new standard 
scheme with 6 × 0.5 Gy into account, these risks are additionally halved.
This risk (max. 1/1000, very likely much lower) must be seen in relation to the tumor risk of 
the not additionally radiotherapeutical‐treated population. In 2008, the lifetime risk of a man 
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in Germany to suffer from cancer was 50.7% (25.9% to die from malignancy), in women 42.8% 
and 20.2% respectively [62].
By limiting the application of LD‐EBRT treatment to patients > 30 years of age, an exposure of 
the juvenile “relatively higher risk” patient population is avoided.
4. Future perspectives: Definition of questions in further randomized 
trials and future research
4.1. Target volume definition in LD‐EBRT
Traditionally target volume definition has been quite large. Field sizes of 12 × 17cm were treated, 
including the entire dorsal and middle foot, and not just the calcaneus [37, 82] (Figure 3A).
Figure 3. Field definitions in LD‐EBRT of a painful plantar heel spur/fasciitis. (A) traditional field definition including 
the entire dorsal and middle foot. (B) In randomized trials and large prospective series commonly used field definition 
encompassing the entire calcaneus, including insertion of the plantar fascia and the Achilles tendon. (C) Proposed small 
field definition for localized painful plantar fasciitis/plantar spur, encompassing only the painful area with 2 cm margins 
extending into the neighboring areas (calcaneus, fascia, fat pad).
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In the recent randomized trials and prospective observational studies target volume defini‐
tion was more restricted and confined to the calcaneus (Figure 3B). “The target volume con‐
sisted of the calcaneus and the region of the plantar aponeurosis” [26]. “The ventral margin 
is corresponding to the ventral surface of the calcaneus, the plantar and dorsal margins are 
surrounding the soft‐tissue border, and the cranial margin is below the ankle” [30]. “Target 
volume is the calcaneus, normally with a field size of 6 cm × 8 cm” [32]. “The calcaneus and 
the plantar aponeurosis were included in the target volume” [25].
In a German national survey 2001 on LD‐EBRT of painful heel spurs the target volume defini‐
tion “large” (dorsal and middle foot) vs. “small” (entire calcaneus) was not correlated with 
treatment outcome [83]. Consequently, very large field definitions should be regarded as 
obsolete.
However, as the pathophysiological cause of calcaneodynia is thought to be a localized 
inflammatory process (see Section 1), it is questionable, whether the entire calcaneus has to be 
irradiated (as long as there are not a plantar as well as a painful dorsal spurs). There are some 
clinical data that support a further restriction of target volume definition.
Field sizes have been given in the study by Miszczyk et al. on 327 patients treated with 
X‐ray beams [39]. Target volume was “… the insertion of the plantar fascia with a cal‐
caneal spur and a reasonable margin. The field size varied from 27 to 150 cm2 (mean 47 
cm2).” However, although not explicitly stated, no correlation was found between field size 
and duration of pain relief after LD‐EBRT. Treatment efficacy in itself was apparently not 
investigated.
In the above‐mentioned series of 285 heels Hermann et al. analyzed treatment efficacy in 
dependence of field sizes, too [38]. The mean field size was 74 cm2. No correlation between 
field size (smaller vs. larger than 74 cm2) with treatment efficacy was found. Further analyses 
of small fields (< 6 × 6 cm), medium‐sized fields (36–64 cm2) and larger fields revealed no 
significant differences.
This is why it seems to suffice to encompass the painful region with 2 cm margins extending 
into the neighboring areas (calcaneus, fascia, fat pad; Figure 3C). However, this recommen‐
dation is deducted from pathophysiological considerations and the above‐mentioned case 
series. A randomized trial is necessary to proof clinical equivalence of a field definition “entire 
calcaneus” (Figure 3B) vs. “insertion of the plantar fascia” (Figure 3C).
4.2. Fractionation of LD‐EBRT
The optimal fractionation schedule has not been elucidated yet. All randomized trial used 
twice weekly treatments. Only one experimental arm was scheduled three times a week [25]. 
In a National Survey in Germany with 146 answering institutions, about 45% applied two 
fractions and 37.5% three fractions weekly [83].
Interestingly, in the landmark study by von Pannewitz a fractionation schedule of only once 
per week was established [34]. Until now, there is no proof of a higher efficacy applying LD‐
EBRT twice or three times per week.
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In radiotherapy of another benign disease (endocrine orbitopathy) a 1 Gy per week over 20 
weeks schedule was more effective than the standard schedules (10 × 2 Gy or 10 × 1 Gy every 
working day) [84]. Although other immunological mechanisms cause endocrine orbitopathy 
in comparison with plantar fasciitis, there is sufficient clinical evidence to test in a random‐
ized trial different fractionation schedules (twice a week vs. once a week, possibly thrice a 
week).
4.3. Comparison of LD‐EBRT with other therapies
Other therapies than LD‐EBRT have been applied in painful heel spur. In the following, just 
a rough overview can be given.
Different kinds of insoles and foot orthoses have been developed. The goal was to reduce 
plantar contact pressure and to distribute the pressure uniformly over the whole rearfoot [63]. 
Magnetic insoles do not seem to provide additional benefit [64]. As a short‐term treatment, 
low‐Dye taping techniques are often used. However, in a randomized trial only a modest 
improvement in ‘first‐step’ pain was seen in comparison with sham‐intervention [65].
Manual stretching is often recommended. A systematic review of six studies found only sta‐
tistically significant differences in comparison with the control in one study combining calf 
muscle and plantar fascia stretches [66].
Several trials have investigated acupuncture. A systematic review from 2010 showed (limited) 
evidence for the effectiveness [67]. A randomized trial published in 2014 recruited 84 patients 
[68]. The authors concluded, that “dry needling provided statistically significant reductions 
in plantar heel pain, but the magnitude of this effect should be considered against the fre‐
quency of minor transitory adverse events.”
Ultrasound therapy has led to questionable results [69], but a randomized trial on cryo‐ultra‐
sound with about 100 patients published in 2014 showed good effectiveness [70].
Low‐level laser light (635 nm), given twice a week for a total of six applications, reduced in a ran‐
domized trial VAS scores significantly after 8 weeks in comparison with placebo [71]. However, 
the study comprised of just 69 patients; other similar studies have not been reported so far.
Extracorporeal shock waves are widely applied. Three metaanalyses comprising at least five 
randomized trials found significant short‐term pain relief and improved functional outcomes 
for this therapeutic option [72–74]. Another study compared the analgesic efficacy of ultra‐
sound and shock wave therapy in 47 patients [75]. The results suggested that the shock wave 
therapy had greater analgesic efficacy.
Another basic approach is the oral administration of nonsteroidal anti‐inflammatory drugs 
(NSAID) to achieve a symptomatic relief. Injections into the painful area are also recommended. 
A recent review summarized ten randomized trials on corticosteroid injections into the plantar 
fascia [76]. A significant effect of the steroids on the pain has been shown. However, it was 
usually short‐term, lasting 4–12 weeks in duration. No advantage of ultrasound‐guided injec‐
tion techniques in comparison with palpation guidance was found, and no superiority of one 
type of corticosteroid over another was seen. A longer lasting pain relief has been suggested 
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by a small randomized trial of botulinum toxin injections [77]. Another option is the injec‐
tion of autologous platelet‐rich plasma. A recent review identified three randomized trials, all 
showing promising results [78]. However, a very small trial challenged this method of plasma 
preparation, as the same clinical effectivity was observed after the injection of whole blood [79].
Different surgical approaches have been developed. Releases of the plantar fascia are done, 
in some studies combined with a spur resection [80]. Due to a probably faster recovery after 
surgery with comparable functional results endoscopic procedures are recommended nowa‐
days [81]. Surgery is usually indicated after failure of conservative therapies as the ultimate 
“salvage‐therapy.”
There is only a limited amount of studies randomizing patients between LD‐EBRT and the 
above‐mentioned alternative therapies.
Canyilmaz et al. randomized 123 patients between LD‐EBRT (6 × 1 Gy, three times a week) 
and 1 ml injection of 40 mg methylprednisolone and 0.5 ml 60 mg 1% lidocaine under the 
guidance of palpation [85]. After 3 and 6 months, VAS values and CS‐scores were compared 
between both groups. After 3 months, the results in the radiotherapy arm were significantly 
superior compared with those after injections.
To corroborate these findings, similar studies should be conducted. Furthermore, more stud‐
ies randomizing LD‐EBRT against other therapies (e.g. extracorporeal shock waves) are 
needed. A minimum size of 50 patients per treatment arm should be assured to gain more 
statistically relevant results. Recruiting patients without prior excessive other therapies for 
these studies would be optimal.
The goal must be an evidence‐based algorithm defining the therapeutic sequence of the dif‐
ferent conservative treatment modalities for plantar fasciitis.
5. Conclusions
LD‐EBRT for painful plantar fasciitis/heel spur is an effective and safe treatment option for 
patients over 30 years of age and after exclusion of pregnancy. A fractionation of 6 × 0.5 Gy 
twice weekly up to a total dose of 3 Gy is currently recommended. In the case of an insuffi‐
cient response a second course can be offered to the patient.
Randomized trials on target volume definition and further optimization of LD‐EBRT fraction‐
ation are currently in the process of planning. Further trials to compare the different conserva‐
tive therapies for plantar fasciitis with each other are necessary to allow the development of 
an evidence‐based treatment algorithm.
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AP anterior‐posterior
CI confidence interval
CR complete remission
CS Calcaneodynia score
Cu chemical element symbol for copper
EC endothelial cells
GCG‐BD German Cooperative Group on Radiotherapy for Benign 
Diseases
Gy Gray
ICRP International Commission on Radiological Protection
IL interleukin
iNOS inducible nitric oxide synthases
KV kilovoltage
LD‐EBRT low dose external beam radiotherapy
mA milliampere
mRNA messenger ribonuclein acid
mSv milliSievert
MV megavoltage
NC no change
NF‐κB nuclear factor kappa B
NO nitric oxide
NSAID non‐steroidal anti‐inflammatory drug
PBMC peripheral blood mononuclear cells
PR partial remission
QOL quality of life
ROS reactive oxygen species
SSD skin‐to‐source distance
TGF‐β
1
transforming growth factor β
1
VAS visual analogue scale
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